HNF is excited to hold the 2nd Annual Patient-Centered Summit with a focus this year on CMT/HNPP and Pain in Cambridge, MA! The Summit will be held on the campus of the Massachusetts Institute of Technology (MIT) in the Samberg Conference Center.
Registration opening soon. Click here for information more information.
Want to help fund research and spread awareness? Well here is your chance and mingle with friends and family while you dine!
HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.
Sufferers of Lyme Disease and Charcot-Marie- Tooth often share many commonalities about their disease
Cheryl and Robert made the altruistic decision to ask their wedding guests to make a donation to HNF in lieu of traditional gifts.
You can join us, and truly make a difference. Register to be a Team CMT member and you’ll be part of an international effort to change the future for those living with CMT.
Her sister was diagnosed with CMT when she was 14, and since then her and many family members have become very familiar with the disease and have worked to raise awareness.
The HNF family has lost two great people this summer: Franklin G. Downing Sr. (father of board member Matthew Downing) and George G. Gatta (father of board member Kathleen Zappola).
As Chief Science Officer of HNF, it is his responsibility to oversee the success of our TRIAD research program in which we fund translational research (pre-clinical and clinical), projects. HNF’s goal is to expedite the research process from bench to bedside.
Nadia Litterman, PhD is Collaborations Director at Collaborative Drug Discovery (CDD), where she aims to identify and develop collaborations for drug discovery using CDD’s innovative informatics technologies.
In previous collaborative work with a group of investigators including Dr Rolf Renne from the University of Florida, Dr. Alex Murashov from East Carolina University and Dr. Lynn Hudson from the NIH-NINDS, we validated a microRNA known as miR29a as a reagent that corrected the expression level of PMP22 in rodent Schwann cells.
Does anyone know the difference between CMT and HNPP. I have read that they come under the same umberella. I have HNPP and so do two of my sisters. We have a wide range of symptoms, with various disabilities. I need a walking stick to move about and most days I can’t walk more than a few metres. My elder sister, who was first diagnosed with HNPP, 20+ years ago, can walk around and goes on holiday two ot three times a year. I would be interested to find out about the difference and similarities in the two diseases.
Thank you.
Carol.